StockData
Thermo Fisher Scientific Inc. logo

Thermo Fisher Scientific Inc.

TMONYSEMeasuring & Controlling Devices, NECFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Oct 30, 2026Score 12/3027% above fair value
$682.65−14.35 (-2.06%)

Close on Nov 2, 2026Market cap $252.41BP/E 36.0Yield 0.25%

Thermo Fisher Scientific Portion of RPO Expected to Be Recognized as Revenue by Quarter

Portion of RPO Expected to Be Recognized as Revenue within Next 12 Months (%)

QuarterlyAnnual

Thermo Fisher Scientific Portion of RPO Expected to Be Recognized as Revenue: 52.0% in Q2 2026, down 2.0 pts from a year earlier.

Latest, Q2 2026
52.0%
Period ended Jun 30, 2026
Change on a year earlier
-2.0 pts
54.0% in Q2 2025
History
27 quarters
Since Q4 2019
Sources
27
Documents cited below

Where the Q2 2026 figure comes from

“Remaining Performance Obligations The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of June 27, 2026, was $ 29.70 billion. The company will recognize revenues for these performance obligations as th”

Source: SEC Form 10-Q (10q_2026Q2, filed 2026-07-31) ↗

Percentage of total RPO expected to convert into revenue within the next 12 months.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPortion of RPO Expected to Be Recognized as Revenue within Next 12 Months (%)Year on yearSource
Q2 2026Jun 30, 202652.0%-2.0 ptsSEC Form 10-Q (10q_2026Q2, filed 2026-07-31) ↗
Q1 2026Mar 31, 202652.0%-2.0 ptsSEC Form 10-Q (10q_2026Q1, filed 2026-05-01) ↗
Q4 2025Dec 31, 202552.0%-1.0 ptsSEC Form 10-K (10k_2025, filed 2026-02-26) ↗
Q3 2025Sep 30, 202553.0%+1.0 ptsSEC Form 10-Q (10q_2025Q3, filed 2025-10-31) ↗
Q2 2025Jun 30, 202554.0%+2.0 ptsSEC Form 10-Q (10q_2025Q2, filed 2025-08-01) ↗
Q1 2025Mar 31, 202554.0%+3.0 ptsSEC Form 10-Q (10q_2025Q1, filed 2025-05-02) ↗
Q4 2024Dec 31, 202453.0%0.0 ptsSEC Form 10-K (10k_2024, filed 2025-02-20) ↗
Q3 2024Sep 30, 202452.0%-1.0 ptsSEC Form 10-Q (10q_2024Q3, filed 2024-11-01) ↗
Q2 2024Jun 30, 202452.0%-4.0 ptsSEC Form 10-Q (10q_2024Q2, filed 2024-08-02) ↗
Q1 2024Mar 31, 202451.0%-6.0 ptsSEC Form 10-Q (10q_2024Q1, filed 2024-05-03) ↗
Q4 2023Dec 31, 202353.0%-2.0 ptsSEC Form 10-K (10k_2023, filed 2024-02-22) ↗
Q3 2023Sep 30, 202353.0%-4.0 ptsSEC Form 10-Q (10q_2023Q3, filed 2023-11-03) ↗
Q2 2023Jun 30, 202356.0%-2.0 ptsSEC Form 10-Q (10q_2023Q2, filed 2023-08-04) ↗
Q1 2023Mar 31, 202357.0%-2.0 ptsSEC Form 10-Q (10q_2023Q1, filed 2023-05-05) ↗
Q4 2022Dec 31, 202255.0%-4.0 ptsSEC Form 10-K (10k_2022, filed 2023-02-23) ↗
Q3 2022Sep 30, 202257.0%-19.0 ptsSEC Form 10-Q (10q_2022Q3, filed 2022-11-04) ↗

Cite this data

StockData. (2026). Thermo Fisher Scientific Portion of RPO Expected to Be Recognized as Revenue (%), quarterly Q4 2019–Q2 2026 [Data set]. Compiled from Thermo Fisher Scientific SEC filings and investor materials. https://stockdatahq.com/stocks/tmo/kpis/rpo-next-12m-pct

See every metric in the Thermo Fisher Scientific KPI table. Data updated Oct 29, 2026.